http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sun Hong Yoo ),( Jung Hyun Kwon ),( Hee Yeon Kim ),( Chang Wook Kim ),( Chan Ran You ),( Sang Wook Choi ),( Se Hyun Cho ),( Joon-Yeol Han ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: The risk of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) is decreased in patients achieved sustained viral response (SVR) after antiviral therapy based on pegylated interferon. However, the increasing risk of HCC development and recurrence in the patients who achieved SVR with all-oral DAA agents is controversy. The aim of this study was to evaluate the de-novo HCC development after antiviral therapy based on all-oral DAA agents in CHC patients without a history of previous HCC. Methods: A total of 963 CHC patients who were treated with interferon free regimen in the 8 affiliated hospitals of the Catholic University of Korea between March 2015 and March 2017 were retrospectively analyzed. De-novo HCC was defined as the newly development of HCC after DAA regimens but no prior HCC history before the DAA treatment. Results: Of the 963 patients, a total of 574 patients received DAA treatment who were followed up for at least 12 weeks with no history of previous HCC. The overall median follow-up period from the start of antiviral therapy was 10.4 months. SVR was achieved in 548 of the 574 (95.5%) patients. De-novo HCC was detected in 5 of 574 (0.87%) patients during the follow-up period. A univariate analysis showed that liver cirrhosis (p = 0.006) and a higher level of serum alpha fetoprotein (AFP) at the time of end treatment response (ETR) (p = 0.010) were significantly associated with HCC development. However, a multivariate analysis indicated a higher level of serum AFP at the time of ETR (p = 0.044, HR 11.80, 95% CI: 1.07-130.44) was the independent risk factor for HCC development. Conclusions: Our study demonstrates that there still exists a risk of newly HCC development in patients treated with all-oral-DAA agents for CHC. Also, serum AFP at the time of ETR was associated with HCC development and it may be a useful biomarker for the prediction of HCC development after all-oral-DAA agents for CHC.
( Hee Yeon Kim ),( Chang Wook Kim ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( Sun Hong Yoo ),( Jung Hyun Kwon ),( Soon Woo Nam ),( Myeong Jun So 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Regorafenib is an oral multikinase inhibitor indicated as second-line therapy for patients with advanced hepatocellular carcinoma (HCC) who have progressed after sorafenib. This study aimed to assess the clinical efficacy and safety of regorafenib in real life. Methods: Consecutive patients between August 2017 and December 2019 with advanced HCC receiving regorafenib were retrospectively included from seven University hospitals in Korea. Radiological responses and adverse events were evaluated using the modified Response Evaluation Criteria in Solid Tumors and the Common Terminology Criteria for Adverse Events version 4.0, respectively. Results: A total of 96 patients were administered regorafenib as second-line therapy after progression on sorafenib. Eighty-eight (91.7%) and 82 (85.4%) patients were classified as BCLC stage C and Child-pugh A. The median follow up was 6.2 months (range 0.5-23.6) after initiation of regorafenib commencement. The median progression-free survival was 4.2 months (95% CI, 2.8-5.6months), and the median overall survival (OS) was 14.0 months (95% CI, 9.0-19.0 months). The most common grade 3-4 toxicities were hand-foot skin reaction (n=9, 9.4%) and increased aspartate aminotransferase (n=4, 4.2%). Twenty seven out of 83 patients who had discontinued regorafenib received sequential systemic therapy after regorafenib. Conclusions: Our real life data demonstrate that regorafenib is a well-tolerated and effective treatment option for patients with advanced HCC who have progressed after sorafenib.
( Hee Yeon Kim ),( Chang Wook Kim ),( Sang Wook Choi ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( Sun Hong Yoo ),( Jung Hyun Kwon ),( Soon Woo Na 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: Hepatocellular carcinoma (HCC) patients often have cirrhosis, and the severity of liver dysfunction influence the prognosis of HCC. Albumin-Bilirubin (ALBI) grade is a recently introduced measurement for hepatic reserve in HCC patients. We aimed to investigate the prognostic value of ALBI grade in advanced HCC patients in a hepatitis B-virus endemic area. Methods: A total of 411 consecutive advanced HCC patients in Child-Pugh A receiving sorafenib monotherapy from September 2008 to October 2017 were evaluated. Overall survival (OS) was assessed using the Kaplan-Meier method and a Cox proportional hazard model. Results: Hepatitis B virus-related HCCs comprised 73.9% (304/411) of enrolled patients. Among 411 enrolled patients, 113 patients (27.5%) were classified as ALBI grade 1 and 298 patients (72.5%) were classified as ALBI grade 2 in baseline. Majority of the patients with ALBI grade 1 (110/113, 97.3%) had a Child-Pugh score of 5. Among patients with ALBI grade 2, 60.7% (181 patients) had a Child-Pugh score of 6. The median OS was 24.5 and 10.8 months for ALBI grade 1 and 2, respectively (P<0.001). Cox regression analysis showed that baseline ALBI grade 2 strongly influenced the mortality of HCC patients receiving sorafenib [Hazard ratio = 2.29 (95% CI: 1.60-3.27, P<0.001)]. Conclusions: ALBI grade could predict the overall survival of advanced HCC patients in Child-Pugh A treated with sorafenib in a hepatitis B virus-endemic area.
홍연웅,오병훈,Hong, Yeon-Uing,O, Byeong-Hun 한국데이터정보과학회 1995 한국데이터정보과학회지 Vol.6 No.1
이동전화 서비스에 대한 가입자수는 중단기적으로 급격히 증가하지만 장기적으로는 대체서비스의 개발 등의 영향으로 그 증가율이 감소하는 특징을 가지고 있다. 본 연구에서는 이동전화 수요에 영향을 미치는 사회 경제 및 기술적 변수들에 대한 통계분석과 아울러 우리나라의 이동전화 가입자수를 예측하였다. 수요의 특성에 따라 로지스틱모형과 이동평균모형을 적용하여 예측한 결과 2001년에는 660만명에 달하여 이동전화의 대중화 시대가 본격적으로 전개될 전망이다.
보급형 휠체어 계단 이동 보조기기의 능동 계단 진입을 위한 계단 형상 추정 기법에 대한 연구
엄수홍(Su-Hong Eom),류중현(Jung-Hwun Ryu),박나연(Na-Yeon Park),이철우(Chol-U Lee),이응혁(Eung-Hyuk Lee) 대한전기학회 2021 대한전기학회 학술대회 논문집 Vol.2021 No.10
The paper is the method that a assistive movement device based on platform of separable type of caterpillar for moving a wheelchair enables to perceive stairs figure autonomously. The proposed recognition method is effective with using RGBD camera and LiDAR based sensors but these sensors are not cheep enough to distribute the assistive movement device at low price. Therefore, we use mechanical structure of the caterpillar based on low cost camera and ultrasonic sensors used in an assistive parking system of vehicle for estimating stairs shape. The method estimates height and landing of stairs over 90 percent accuracy, which yields gradient of staircase.